When former cancer researcher Professor Andrew Wilks and chemist Dr Christopher Burns invented the drug now called Momelotinib in 2001 at Cytopia, a biotech company founded by Wilks, they didn’t know it would be only the second Australian drug discovery ever to be approved by the US Food and Drug Administration.
Burns is now the CEO and Managing Director of Amplia, a biotech developing drugs that amplify the effects of other, standard treatment drugs (such as those used to treat pancreatic cancer); and Wilks is the co-founder and CEO of SYNthesis Group, a fund that invests in early stage therapeutics, from discovery through preclinical proof of concept.
Food for thought ...
.
ATX Price at posting:
8.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)